Biomerica's Q3 revenue falls, net loss widens on lower manufacturing sales

Biomerica

14/04/2026 24:13

Overview

Medical diagnostics provider's fiscal Q3 revenue fell yr/yr due to lower contract manufacturing sales

Company posted wider net loss and negative gross margin for the quarter

European revenue rose 45% and over-the-counter product lines grew 16% yr/yr

Outlook

Company expects gross margin to improve as inFoods IBS and hp+detect sales scale

Biomerica sees improved CDMO customer demand after quarter end

Result Drivers

CONTRACT MANUFACTURING DECLINE - Lower contract manufacturing revenue after completion of prior projects weighed on Q3 sales

PRODUCT MIX SHIFT - Negative gross margin driven by lower sales volume and changes in product mix

R&D EXPENSES DOWN - R&D expenses fell 24% yr-to-date as development phases ended for key products

Company press release: ID:nGNXFkyTH

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
$990,000
Q3 Net Income
-$1.31 mln
Q3 Gross Margin
-4%
Q3 Operating Expenses
$1.25 mln
Q3 Operating Income
-$1.30 mln


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)